Chitosan/cyclodextrin nanoparticles can efficiently transfect the airway epithelium in vitro

Teijeiro‐Osorio, Desirée; Remuñán‐López, Carmen; Alonso, Marı́a José

doi:10.1016/j.ejpb.2008.09.020

Cited by 94 publications

(42 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All these properties, place chitosan as a potential alternative to administrate drugs to or through the lung. There are reports showing the effectiveness of chitosan increasing lung retention of drugs (Grenha et al, 2005;Li and Birchall, 2006;Teijeiro-Osorio et al, 2009). …”

Section: Discussionmentioning

confidence: 99%

Chitosan as a non-viral co-transfection system in a cystic fibrosis cell line

Fernández

Santos-Carballal

Weber

et al. 2016

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Successful gene therapy requires the development of suitable vehicles for the selective and efficient delivery of genes to specific target cells at the expense of minimal toxicity. In this work, we investigated a non-viral gene delivery system based on chitosan (CS) to specifically address cystic fibrosis (CF). Thus, electrostatic self-assembled CS-pEGFP and CS-pEGFPsiRNA complexes were prepared from high-pure fully characterized CS (Mw ~20 kDa and degree of acetylation ~30%). The average diameter of positively-charged complexes (i.e.  ~ +25 mV) was ~200 nm. The complexes were found relatively stable over 14 h in OptiMEM. Cell viability study did not show any significant cytotoxic effect of the CS-based complexes in a human bronchial cystic fibrosis cell line (s). We evaluated the transfection efficiency of this cell line with both CS-pEGFP and co-transfected with CS-pEGFP-siRNA complexes at (N/P) charge ratio of 12. We reported an increase in the fluorescence intensity of CS-pEGFP and a reduction in the cells co-transfected with CS-pEGFP-siRNA. This study shows proof-of-principle that co-transfection with chitosan might be an effective delivery system in a human CF cell line. It also offers a potential alternative to further develop therapeutic strategies for inherited disease treatments, such as CF.

show abstract

Section: Discussionmentioning

confidence: 99%

Chitosan as a non-viral co-transfection system in a cystic fibrosis cell line

Fernández

Santos-Carballal

Weber

et al. 2016

International Journal of Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…In fact, in a Calu-3 cell culture model, chitosan/cyclodextrin nanoparticles were shown to cause a reversible reduction in the transepithelial resistance of the cell monolayer, thus increasing the membrane permeability (79) and to have the ability to enter epithelial cells and promote gene expression (80). These nanoparticles presented an adequate size range (100-200 nm, depending on chitosan molecular weight, MW), a positive surface charge (+22 to +35 mV) and very high DNA association efficiency (>90%).…”

Section: Chitosan-based Nanoparticlesmentioning

confidence: 99%

“…Furthermore, these nanoparticles exhibited a low toxicity. Considering all these observations, these nanocarriers represent a promising approach for gene therapy at the level of mucosal surfaces and, in particular, the respiratory mucosa (79,80).…”

Section: Chitosan-based Nanoparticlesmentioning

confidence: 99%

“…Later on, the composition and structure of these nanopacrticles was adapted for different applications and administration routes. Hence, a new generation of safe hybrid nanoparticles consisting of chitosan and either anionic hyaluronic acid or cyclodextrin derivatives were developed intended for pulmonary and nasal delivery of peptides (78,79) and gene therapy (80). TEM microphotographs of the chitosan nanoparticles formulations are shown in Figure 2.…”

Section: Chitosan-based Nanoparticlesmentioning

confidence: 99%

See 1 more Smart Citation

The potential of chitosan for pulmonary drug delivery

Grenha

Al‐Qadi

Seijo

et al. 2010

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

A Grenha, S Al-Qadi, B Seijo, C Remuñán-López, 2010. AbstractThe administration of drugs through the pulmonary route offers great advantages, but also requires overcoming many challenges. There is a need to develop appropriate carriers for each active molecule to be delivered to the desired site in the lung, either for a local or a systemic effect. The polysaccharide chitosan is a very promising material for this purpose, given its demonstrated properties of biodegradability and biocompatibility, as well as mucoadhesivity and ability to enhance macromolecules permeation. In this review, the potential of chitosan to develop drug carriers for delivery to the lung will be discussed.The most important features that can support its selection will be explained. Besides, different approaches to increase its performance, especially concerning solubility, permeation-enhancing properties and gene transfection efficiency, will be presented.Special emphasis will be placed on information of different chitosan-based carriers, namely nanoparticles and microparticles, intended for pulmonary drug delivery.3

show abstract

“…Using in vitro studies, nanocarriers with nanoemulsion-producing techniques have been reported to be an efficient delivery system across various indications (6)(7)(8)(9). We are also proposing that our dextran-containing nano-carriers can also be an efficient way of delivering media to the bioreactor, a possibility receiving some sort from the recent report that dextran nanobubbles enhance oxygen delivery (10).…”

Section: Introductionmentioning

confidence: 93%

Dextran-based Nanocarriers as Efficient Media Delivery Vehicles to Cell Production Bioreactors

Anton¹,

Kambalapally²,

Thomas³

et al. 2010

Nano BioMed ENG

View full text Add to dashboard Cite

Decreasing the volume of media required to maintain cell viability not only reduces contamination of bioreactors from the upstream process, but may contribute to cost-containment measures in the biopharmaceutical industry. Based on our recent finding that dextran-containing nanocarriers increased CHO cell density up to 20 fold compared to its cellulose-containing microcarrier counterpart (manuscript submitted), we then investigated the possibility of reducing media volume to maintain cell viability, by utilizing the same dextran-based nanocarrier prepared from a self assembling nanoemulsion (SANE) method, and an adherent Chinese hamster ovary (CHO) cell culture line to evaluate media volume requirements. At the same 60 mL volume of media, cell viability after day 3 was 6 fold greater in CHO cells exposed to dextran-containing nanocarriers compared to cellulose-based microcarriers. When CHO cells were exposed to 60 mL of media containing dextran-based nanocarriers compared to 100 mL of media for cellulose-microcarriers, at day 6, cell density was up to 7 fold greater. Similarly, cell lysate protein concentrations at day 6 was nearly 3 fold greater for CHO cells exposed to dextran-containing nanocarriers compared to the cellulose-based microcarriers. Furthermore, nanocarriers had 59% greater glucose concentration, used as a measure of the polymer dextran and cellulose content levels in the nanocarriers and microcarriers, respectively. In conclusion, nanocarriers with increased numbers of dextran molecules, developed in these studies may be useful to further optimize media volume requirements for maximum culture growth.

show abstract

Chitosan/cyclodextrin nanoparticles can efficiently transfect the airway epithelium in vitro

Cited by 94 publications

References 27 publications

Chitosan as a non-viral co-transfection system in a cystic fibrosis cell line

Chitosan as a non-viral co-transfection system in a cystic fibrosis cell line

The potential of chitosan for pulmonary drug delivery

Dextran-based Nanocarriers as Efficient Media Delivery Vehicles to Cell Production Bioreactors

Contact Info

Product

Resources

About